SMNR on OTC
Semnur Pharmaceuticals, Inc.
American pharmaceutical preparations company, incorporated in Delaware. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Contineum Therapeutics, Inc., Lexicon Pharmaceuticals or Gossamer Bio, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Research and development3¢$1.7M
- Other costs96¢$48.2M
- Interest0¢$96.2K
Out of $50.0M in revenue.43 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $2.5M | $1.7M |
| General and administrative | $157.9M | $3.0M |
| Total operating expenses | $160.4M | $4.7M |
| Loss from operations | -$160.4M | -$4.7M |
| Net loss and comprehensive loss | -$160.4M | -$4.7M |
| Net loss per share, basic | -$0.78 | -$0.02 |
| Net loss per share, diluted | -$0.78 | -$0.02 |
| Weighted average shares of common stock outstanding, basic | 204.8M shares | 200.0M shares |
| Weighted average shares of common stock outstanding, diluted | 204.8M shares | 200.0M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $20.0K | $12.0K | |
| Prepaid expenses | $576.0K | $2.0K | |
| Other current assets | $0 | $6.0M | |
| Total current assets | $596.0K | $6.0M | |
| Property and equipment, net | $750.0K | $689.0K | |
| Total assets | $1.3M | $6.7M | |
| Accounts payable | $5.9M | $0 | |
| Accrued expenses | $739.0K | $35.0K | |
| Promissory notes | $3.5M | $0 | |
| Total current liabilities | $10.2M | $35.0K | |
| Related party loan | $11.9M | $49.4M | |
| Total liabilities | $22.1M | $49.5M | |
| Preferred stock, $0.0001 par value, 45,000,000 shares authorized as of December 31,2025 and December 31, 2024; 5,423,606 and no shares issued and outstanding as of December 31, 2025 and 2024, respectively | $1.0K | $0 | |
| Common stock, $0.0001 par value, 740,000,000 and 200,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 230,209,142 and 200,000,000 issued and outstanding as of December 31, 2025 and 2024, respectively | $23.0K | $20.0K | |
| Additional paid-in capital | $255.0M | $72.6M | |
| Accumulated deficit | -$275.8M | -$115.4M | |
| Total stockholders' deficit | -$20.8M | -$42.8M | -$38.1M |
| Total liabilities and stockholders' deficit | $1.3M | $6.7M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 45.0M shares | 45.0M shares | |
| Preferred stock, shares issued | 5.4M shares | 0 shares | |
| Preferred stock, shares outstanding | 5.4M shares | 0 shares | |
| Common stock, per value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized | 740.0M shares | 200.0M shares | |
| Common stock, shares issued | 230.2M shares | 200.0M shares | |
| Common stock, shares outstanding | 230.2M shares | 200.0M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $20.0K | $12.0K | |
| Prepaid expenses | $576.0K | $2.0K | |
| Other current assets | $0 | $6.0M | |
| Total current assets | $596.0K | $6.0M | |
| Property and equipment, net | $750.0K | $689.0K | |
| Total assets | $1.3M | $6.7M | |
| Accounts payable | $5.9M | $0 | |
| Accrued expenses | $739.0K | $35.0K | |
| Promissory notes | $3.5M | $0 | |
| Total current liabilities | $10.2M | $35.0K | |
| Related party loan | $11.9M | $49.4M | |
| Total liabilities | $22.1M | $49.5M | |
| Preferred stock, $0.0001 par value, 45,000,000 shares authorized as of December 31,2025 and December 31, 2024; 5,423,606 and no shares issued and outstanding as of December 31, 2025 and 2024, respectively | $1.0K | $0 | |
| Common stock, $0.0001 par value, 740,000,000 and 200,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 230,209,142 and 200,000,000 issued and outstanding as of December 31, 2025 and 2024, respectively | $23.0K | $20.0K | |
| Additional paid-in capital | $255.0M | $72.6M | |
| Accumulated deficit | -$275.8M | -$115.4M | |
| Total stockholders' deficit | -$20.8M | -$42.8M | -$38.1M |
| Total liabilities and stockholders' deficit | $1.3M | $6.7M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 45.0M shares | 45.0M shares | |
| Preferred stock, shares issued | 5.4M shares | 0 shares | |
| Preferred stock, shares outstanding | 5.4M shares | 0 shares | |
| Common stock, per value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized | 740.0M shares | 200.0M shares | |
| Common stock, shares issued | 230.2M shares | 200.0M shares | |
| Common stock, shares outstanding | 230.2M shares | 200.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$160.4M | -$4.7M |
| Stock-based compensation | $142.4M | $660.0K |
| Prepaid Expenses | -$586.0K | $0 |
| Other assets | $9.9M | $0 |
| Accounts payable | $2.1M | $0 |
| Accrued expenses | $704.0K | -$861.0K |
| Net cash used in operating activities | -$5.9M | -$4.9M |
| Proceeds from Business Combination | $27.0K | $0 |
| Proceeds from related party loan | $5.8M | $4.9M |
| Net cash provided by financing activities | $5.9M | $4.9M |
| Net change in cash and cash equivalents | $8.0K | $0 |
| Net liabilities assumed in Business Combination | $12.9M | $0 |
| Related party loan settled in preferred stock pursuant to Debt Exchange Agreement | $54.2M | $0 |
| Related party loan settled in common stock | $1.0M | $0 |
| Promissory notes settled in common stock | $125.0K | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led Semnur Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.
Board members and other officers (6)
- Board memberDorman Followwill Sep 23, 2025 to now10
- Board memberJay Chun Sep 23, 2025 to now11
- Board memberYue Alexander Wu Sep 23, 2025 to now12
- Board memberAnnu Navani Sep 26, 2025 to now13
- Board memberJim Mao Apr 6, 2022 to Apr 6, 202214
- Board memberKevin Vassily Apr 6, 2022 to Apr 6, 202215
Former names
- Denali Capital Acquisition Corp.Mar 1, 2022 to Sep 23, 20252
Filings
220 filings to the SEC since October 2021: 4 annual reports, 14 quarterly reports, 46 major events, 23 insider forms, 33 large holders, 100 other. The latest 20:
- Aug 10, 202610-Q EDGAR
- Jul 7, 2026424B3 EDGAR
- Jul 7, 20268-K EDGAR
- Jul 1, 2026424B3 EDGAR
- Jun 26, 2026SCHEDULE 13D/A EDGAR
- Jun 26, 20264 EDGAR
- Jun 25, 20268-K EDGAR
- Jun 15, 2026424B3 EDGAR
- Jun 15, 2026424B3 EDGAR
- May 18, 2026EFFECT EDGAR
- May 13, 202610-Q EDGAR
- May 12, 2026POS AM EDGAR
- Apr 30, 2026ARS EDGAR
- Apr 30, 2026DEF 14A EDGAR
- Apr 23, 20268-K EDGAR
- Mar 17, 20268-K EDGAR
- Feb 27, 202610-K EDGAR
- Dec 29, 2025EFFECT EDGAR
- Dec 29, 2025424B3 EDGAR
- Dec 23, 2025CORRESP EDGAR
The 220 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
3 open-market trades by officers, directors and large owners since October 2021: 2 buys and 1 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 23, 2025 | Scilex Holding Co10% owner | Sale | 12,500,000 | $16.00 | $200.0M | Form 4 |
| Apr 11, 2022 | Denali Capital Global Investments LLC10% owner | Buy | 510,000 | $10.00 | $5.1M | Form 4 |
| Apr 11, 2022 | Xu Jiandong10% owner | Buy | 510,000 | $10.00 | $5.1M | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- METEORA CAPITAL, LLCSCHEDULE 13G/A, 8 filings Nov 7, 2023 to Aug 14, 202516
- TD SECURITIES (USA) LLCSCHEDULE 13G/A, 2 filings Dec 26, 2024 to Aug 12, 202517
- GLAZER CAPITAL, LLCSC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202418
- Polar Asset Management Partners Inc.SC 13G/A, 3 filings Feb 10, 2023 to Nov 14, 202419
- Denali Capital Global Investments LLCSC 13G/A, 2 filings May 16, 2023 to Sep 16, 202420
- Shaolin Capital Management LLCSC 13G/A, 2 filings Feb 14, 2023 to Feb 22, 202421
- ATW SPAC MANAGEMENT LLCSC 13G/A, 2 filings Feb 14, 2023 to Feb 13, 202422
- BOOTHBAY FUND MANAGEMENT, LLCSC 13G/A, 2 filings Feb 10, 2023 to Feb 13, 202423
- Hudson Bay Capital Management LPSC 13G/A, 2 filings Feb 7, 2023 to Feb 2, 202424
- Lawrence FeisSC 13G/A, 2 filings Oct 20, 2022 to Jan 31, 202325
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| GAMMA Investing LLC | 116 | $58 | 0.0% | New |
| Rhumbline Advisers | 30 | $15 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8SEC EDGARHenry Ji, Chair
- 9SEC EDGARYou Sun, Chief financial officer
- 10SEC EDGARDorman Followwill, Board member
- 11SEC EDGARJay Chun, Board member
- 12SEC EDGARYue Alexander Wu, Board member
- 13SEC EDGARAnnu Navani, Board member
- 14SEC EDGARJim Mao, Board member
- 15SEC EDGARKevin Vassily, Board member
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25